A case report of small cell ovarian neuroendocrine carcinoma combined with immunochemotherapy

Small cell ovarian neuroendocrine (NE) carcinoma is a rare NE tumor with a low incidence, poor prognosis, and no standardized treatment. To date, there have been no clear reports on the efficacy or prognosis of combined immunological and chemotherapy-based approaches in patients with this type of tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yuan-Xue, Gao, Xiang-Peng, Xin, Lei, Jia, You-Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
3600
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678510/
https://www.ncbi.nlm.nih.gov/pubmed/36401483
http://dx.doi.org/10.1097/MD.0000000000031445
Descripción
Sumario:Small cell ovarian neuroendocrine (NE) carcinoma is a rare NE tumor with a low incidence, poor prognosis, and no standardized treatment. To date, there have been no clear reports on the efficacy or prognosis of combined immunological and chemotherapy-based approaches in patients with this type of tumor. METHODS: We administered the immune checkpoint inhibitor tirelizumab (PD-1 mab), in combination with etoposide and cisplatin chemotherapy (EP), to a patient with small cell ovarian NE carcinoma to examine its efficacy and safety. RESULTS: The evaluation of efficacy was PR for every 2 courses of application, and immunomaintenance therapy was administered after 6 courses of treatment. CONCLUSION: Our studies indicate that tirelizumab combined with EP, may be an effective treatment for small cell ovarian NE carcinoma.

Ejemplares similares